FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program

MACE/MACE+ endpoints evaluated across CKD patients not on dialysis and on dialysis Superiority in time to first MACE+ versus epoetin alfa in incident dialysis patients
SAN FRANCISCO, May 09, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN) today announced topline results from the pooled safety analyses of the global Phase 3 program for roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI).  The global pivotal Phase 3 trials were conducted by FibroGen and collaboration partners AstraZeneca and Astellas Pharma, Inc., for treatment of anemia in chronic kidney disease (CKD) patients across the non-dialysis-dependent (NDD), incident (newly initia…

Source: Original Article